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Introduction: Factors implicated in influenza-mediated morbidity and mortality include robust cytokine production
(cytokine storm), excessive inflammatory infiltrates, and virus-induced tissue destruction. Tumor necrosis factor-alpha
(TNF-α) is an important pro-inflammatory cytokine present during influenza infection, but it is unclear whether direct
inhibition of TNF-α can elicit protection against influenza infection.
Methods: In this study, the commercially available TNF-α inhibitor etanercept was used to inhibit TNF-α induced by
lethal A/FM/1/47 (H1N1) influenza virus infection of mice. The effects of TNF-α inhibition on mouse survival, pathologic
changes, immune cell infiltration, inflammatory cytokine secretion, Toll-like receptor expression, and activation of the
NF-κB (nuclear factor kappa B) signaling pathway were evaluated.
Results: The intranasal delivery of etanercept provided significant protection against mortality (30% of mice survived
up to 14 days after infection) in mice treated with etanercept. In contrast, no survivors were found beyond 6
days in mice treated with saline after lethal challenge with H1N1 influenza virus. It was observed that etanercept
significantly reduced inflammatory cell infiltration (for example, macrophages and neutrophils), inflammatory
cytokine secretion (for example, interleukin-6, TNF-α, and interferon gamma), and expression of Toll-like receptors
(TLR-3, TLR-4, and TLR-7). Etanercept also downregulated and inhibited the cascade proteins of the NF-κB signaling
pathway (for example, MyD88, TRIF, NF-κB, and p65), as well as enhanced host control of virus replication.
Conclusions: These findings indicate that etanercept, by blocking TNF-α, can significantly downregulate excessive
inflammatory immune responses and provide protection against lethal influenza infection, making its use a novel
strategy for controlling severe influenza-induced viral pneumonia.Introduction
Influenza viruses are a major contributor to morbidity
and mortality in humans, and with their ability to cause
yearly epidemics and occasional pandemics, they represent
a considerable burden to healthcare systems globally [1].
The recent emergence of the avian influenza A (H5N1)
virus, the 2009 pandemic influenza A (H1N1) virus, and
the novel avian influenza A H7N9 virus [2-4] served to
highlight that respiratory viruses are important causative
agents of severe pneumonia. The current battery of* Correspondence: hyzhu@mail.shcnc.ac.cn; dianwenju@fudan.edu.cn
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reproduction in any medium, provided the orantivirals available in clinical practice for the treatment
of viral pneumonia is limited [5]. Thus, the continued
pandemic threat of these circulating viruses makes the
identification and the development of novel therapeutic
strategies an urgent matter.
Factors implicated in the high morbidity and mortality
associated with influenza virus infection include, but are
not limited to, a robust cytokine production (cytokine
storm), excessive inflammatory infiltrates, virusnduced
tissue destruction [6], and secondary bacterial coinfection
[7]. Among these factors, the excessive cytokine response
is considered to be the key contributor [8].
Corticosteroids and cyclooxygenase-2 (COX-2), which
are both inhibitors of inflammation, have been tested as. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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although their effectiveness was shown to be limited
[9-11]. Other novel immunomodulatory drugs, such as
sphingosine-1-phosphate receptors analogs, have been
reported to provide protection against pathogenic influ-
enza virus by suppressing the cytokine storm [12,13].
Therefore, effective inhibition of inflammation appears
to be a promising therapeutic strategy for respiratory
virus infections.
TNF-α, an important inflammatory cytokine, has been
shown to correlate with morbidity and mortality in
macaques [14] and humans [15,16] infected with highly
virulent influenza viruses. However, the role of TNF-α
in virus clearance and immunopathologic lung injuries
during influenza virus infection is still controversial, and
whether direct inhibition of TNF-α can elicit protection
from influenza infection is still unknown.
Etanercept (brand name, Enbrel), an anti-TNF-α agent,
is a fusion protein of the human p75 TNF-α receptor
attached to the Fc portion of human IgG1 [17], which
has been approved for the treatment of rheumatoid
arthritis [18,19]. However, no evidence supports the
protective effects of etanercept against influenza infection.
In this study, a murine model of lethal acute respiratory
H1N1 influenza A infection and etanercept was used to
investigate the immunoregulatory role of TNF-α in viral
clearance, host immune responses, and lung immunopa-
thology. For the first time, our study demonstrated that
the inhibition of TNF-α had a significant effect on the
extent of lung immunopathology and inhibited inflamma-
tory cellular infiltration and cytokine responses. In addition,
we observed a decrease in influenza virus replication and
an increased survival of influenza virus-infected mice.Materials and methods
Experimental infection of mice with a mouse-adapted
H1N1 influenza virus
BALB/c male mice (16 to 18 g) were purchased from the
Shanghai SLACCAS Laboratory Animal Co., Ltd. (Shanghai,
China). Mice were housed under specific pathogen-free
conditions and given free access to sterile water and
standard mouse food. All experimental protocols were
approved by the Animal Experiment Ethics Committee
of Fudan University (Shanghai, China).
The influenza virus strain A/FM/1/47 (H1N1) used in
this study is a highly virulent, mouse-adapted virus that
was isolated from patients at Fort Monmouth, NJ, USA,
during an outbreak in 1947. The virus can cause severe
pneumonia and high mortality in mice (ATCC VR-97).
The virus was supplied by the Shanghai Center for Disease
Control and Prevention (Shanghai, China) and was stored
in aliquots at −70°C. A freshly thawed aliquot was used for
each experiment [20]. The TNF-α inhibitor etanercept wasobtained from Beijing SL Pharmaceutical Co., Ltd. (Beijing,
China).
Mice under isoflurane anesthesia were infected intra-
nasally (i.n.) with 10 TCID50 of A/FM/1/47 (H1N1) [21].
Two hours after infection, mice were i.n. (local adminis-
tration for respiratory system) inoculated with either 30
μl of 0.9% (wt/vol) NaCl (virus control) or 2.5 mg/kg of
etanercept (dissolved in 0.9% (wt/vol) NaCl) twice daily.
An uninfected control group of mice also received 0.9%
(wt/vol) NaCl in the same manner.Mice survival and body-weight loss
For the survival study (n = 10 mice per group), etanercept
or virus control was administered as described for 7 days.
Then, mice were continuously monitored for survival
and body-weight loss for an additional 7 days. These
experiments were repeated 3 times, and we made related
calculations.Histopathology
For histopathologic analysis, experimental infections as
described earlier were performed. On day 4 after infection,
mice (n = 6 per group) were euthanized and weighed.
Lung tissues were harvested and weighed, and the cor-
responding lung/body index was calculated. The left
lobes of the lung were immersed in PBS-buffered formalin,
and were then preserved in paraffin blocks by using
standard procedures. Tissue sections (10 μm) were cut,
placed on glass slides, and stained with hematoxylin
and eosin by using standard techniques.
A tissue-inflammation score was assigned to the analyzed
sections of each lung by using the mean score obtained
from six separate random fields per tissue section. Scores
were assigned according to the percentage of lung patho-
logic congestive involvement, as follows: none, 0; ≤ 25%, 1;
26% to 50%, 2; 51% to 75%, 3; and ≥76%, 4.
Microscopic analysis was carried out by three separate
pathologists who were blinded to the various experimental
treatments.Inflammatory cytokine measurement
On days 2 and 4 after infection, mice (n = 6 per group)
were euthanized, and lung tissues were harvested. These
tissues were individually homogenized in PBS buffer, and
the supernatants were used for inflammatory cytokine
measurement. The quantities of TNF-α, IFN-γ, and IL-6
were determined by using commercial enzyme-linked
immunosorbent assay (ELISA) kits (BD Biosciences) by
following the manufacturer’s instructions. The average
level of inflammatory cytokines was calculated according
to these data from three separate experiments.
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On days 2 and 4 after infection, mice (n = 4 per group)
were euthanized. Lungs were harvested and diced by
using surgical scissors. Diced tissue was suspended in 4
ml of DMEM containing 0.5 mg/ml collagenase from
Clostridium histolyticum type IV (Sigma, USA), 50 U/ml
DNase I (Sigma), and 1 mg/ml trypsin inhibitor type II-s
(Sigma) for 1 hour at 37°C. The suspension was then
crushed through a 40-μm basket filter, and unwanted
red blood cells were lysed by using red blood cell lysis
buffer containing 0.02 Tris–HCl (pH 7.4) and 0.14
NH4Cl. Inflammatory cells were purified by centrifugation
in 35% (vol/vol) PBS-buffered Percoll (GE Healthcare Life
Sciences, USA) at 500 g for 15 minutes. Cell pellets were
resuspended in staining buffer (RPMI-1640 medium), and
Fc receptors were blocked by using 25 μg/ml anti-mouse
CD16/32. Cells were stained with fluorescently labeled
antibodies against the following mouse proteins: CD11b+,
F480-, Ly6G+ (neutrophils), CD11b+, F480+, and Ly6G-
(macrophage/monocytes), CD3e-, CD49b+ [natural
killer (NK) cells], CD3e+, CD19+ (B cells), CD3e+, CD4+
(T-helper cells), CD3e+, and CD8a+ (cytotoxic T cells)
[22,23]. All antibodies were purchased from BD Biosci-
ences (USA). The average counting of immune cells was
calculated from three separate experiments.
Inflammatory signaling pathways (Toll-like receptors and
NF-κB) and influenza virus replication
On days 2 and 4 after infection, mice (n = 6 per group)
were euthanized, and lung tissues were harvested. These
left-lung lobes were homogenized for RNA isolation. The
isolation of total RNA and cDNA synthesis were performed
by using the Trizol reagent (Invitrogen) and PrimeScript
RT reagent Kit (DRR047A; Takara) according to the
manufacturers’ recommendations. The primers for TLR-3,
TLR-4, TLR-7, MyD88, TRIF, NF-κB, the influenza virus
M gene, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were as described in Additional file 1. By using
cDNAs as templates, quantitative real-time PCR was
carried out by using the SYBR Green PCR Master Mix
(Applied Biosystems) in a StepOne Plus Real-Time PCR
Detection System (Applied Biosystems), according to
the manufacturer’s instructions and with the following
thermocycling parameters: 94°C for 5 minutes; followed
by 94°C for 5 seconds, 60°C for 30 seconds for 40 cycles,
with a final melting curve analysis of 60°C to 95°C.
The mRNA expression levels were normalized to the
corresponding expression level of the GAPDH house-
keeping gene. The results of qPCR were from three
separated independent experiments.
The remaining right-lung lobes were used for immu-
nohistochemistry. Tissue sections (10 μm) were cut and
processed as described earlier. The primary antibody,
phospho-NF-κB p65 (Ser536) (93H1) rabbit monoclonalantibody (Cell Signaling Technology, Inc., USA) was used
to evaluate the activation of the inflammatory NF-κB
signaling pathway.
Statistical analyses
All statistical analyses were performed by using GraphPad
Prism for Windows (Version 6.0). The Gehan-Breslow-
Wilcoxon test was used to analyze the survival of mice,
whereas the one-way ANOVA was used to analyze other
experimental data. In all cases, probability values less
than 0.05 (P < 0.05) were taken to indicate statistical
significance.
Results
Administration of the TNF-α inhibitor etanercept
significantly improved survival of H1N1-infected mice
and reduced pulmonary injury
Mice were treated with either saline or etanercept i.n.
after intranasal infection with the lethal mouse-adapted
human influenza virus A/FM/1/47 (H1N1). Etanercept
administration significantly increased the survival of mice,
compared with the control mice (Figure 1A). For recipi-
ents of saline alone, no mice survived beyond 7 days after
infection, whereas 30% of mice that received etanercept
survived until 14 days after infection, which was the
end of the observation period (P < 0.01). In mice treated
with etanercept, body-weight loss ceased on day 4 after
infection and slowly recovered until the end of the
experiment at day 14 (P < 0.05; Figure 1B). Obvious indi-
vidual differences were also observed in etanercept-treated
mice after 7 days, and whether they were related to
ceasing of etanercept will be clarified in future work.
Lung/body index (Figure 1C) demonstrated that infection
with H1N1 caused lung-tissue swelling and the production
of significant amounts of exudate in the control mice. The
administration of etanercept significantly alleviated lung
swelling and exudate, an observation that was confirmed
by the histopathologic analysis. Histopathologic analysis
of lungs from the infected mice treated with etanercept
revealed markedly reduced tissue injury, mononuclear
cell accumulation, hemorrhage, and pulmonary edema
(Figure 1E through H). In addition, etanercept significantly
reduced tissue-inflammation scores compared with con-
trol mice on day 4 after infection (Figure 1D).
Etanercept inhibited the burst of inflammatory cytokines
and the recruitment of innate immune cells induced by
lethal influenza virus infection
Robust innate proinflammatory cytokine expression can
cause direct tissue insult and recruit potentially tissue-
destructive inflammatory cells. We selected three import-
ant inflammatory cytokines (TNF-α, IL-6, and IFN-γ)
to evaluate the cytokine burst in lethally influenza-infected
mice. ELISA results revealed that these cytokines increased
Figure 1 Administration of etanercept protects against lethal H1N1 influenza virus infection and inhibits the immunopathologic
effects associated with infection in vivo. Saline or 2.5 mg/kg of etanercept was administered i.n. to mice 2 hours after i.n. infection with 10 TCID50
of influenza virus A/FM/1/47 (H1N1). (A, B) Mice were monitored for survival and body-weight loss. Data were derived from three separate experiments,
with a total of 30 mice per group (10 mice per group each time). Survival curves show data until day 14 after infection, because further mortality was
not observed at later time points. (C, D) Lung/body weight and inflammation score were evaluated on day 4 after infection. Mice were
weighed (grams) and euthanized. Whole lungs were harvested, weighed (grams), and the corresponding lung/body index was calculated. The
scores were calculated as follows: none, 0; ≤25%, 1; 26% to 50%, 2; 51% to 75%, 3; ≥76%, 4 lung involvement. #P ≤ 0.05 compared with saline
recipients. (E through H) Histopathologic analysis on day 4 after infection was carried out by three separate pathologists who were blinded
to the various experimental treatments.
Shi et al. Critical Care 2013, 17:R301 Page 4 of 9
http://ccforum.com/content/17/6/R301in the virus-infected control mice as expected, but they
were significantly inhibited in mice treated with eta-
nercept (Figure 2A). The recruitment and infiltration
of immune cells can be affected by inflammatory cyto-
kine production. Analysis with flow cytometry revealed
a consistent reduction in the accumulation of macro-
phage/monocytes (Figure 2B) and neutrophils (Figure 2C)
in the lungs of mice treated with etanercept on 2 and 4
days after influenza A virus infection. Many significant
differences were noted in neutrophils accumulation
between virus control and etanercept-treated mice. The
NK cell, an innate immune cell that plays an important
role in controlling and clearing virus, count significantly
decreased after infection. The administration of etanercept
counteracted this reduction in NK cells (Figure 2D).
At these same time points, the adaptive immune cells
(CD4+ Th cells and CD8+ Tc cells) were also evaluated,
but no clear influences of etanercept were observed in
mice at days 2 and 4 after infection (Figure 2E through G).
Even etanercept seems to alleviate the reduction of B
cells after infection, but the possible influence of etanercept
on adaptive immune responses must be explored in
future work.
In agreement with the observations of diminished
inflammation and pulmonary injury after influenza
virus infection (Figure 1C through 1H), etanercept
significantly inhibited inflammatory cytokine produc-
tion as well as the accumulation of innate inflammatory
infiltrates.Etanercept inhibited the activation of the NF-κB signaling
pathway and enhanced host control of influenza
virus replication
Before these experiments, we already used a pair of
housekeeping genes GAPDH and beta-actin to assess
these gene expressions under etanercept treatment, and
we found the normalized results were consistent.
NF-κB (nuclear factor kappa B) family transcription
factors are master regulators of immune and inflamma-
tory processes in response to both injury and infection.
Toll-like receptors (TLRs) recognize specific pathogen-
associated molecular patterns (PAMPs) and can trigger
the activation of the NF-κB pathway. In this study, we
monitored the transcriptional levels of TLR3/7 (specific
for viruses), TLR4, and the downstream adaptor genes
MyD88 and TRIF, and NF-κB p65.
Data from the qPCR revealed that administration of
etanercept resulted in a reduced upregulation of the
virus-specific TLR3 and TLR7 in mice induced by lethal
influenza virus infection (Figure 3A and C), consistent
with the decreased virus replication in mice treated with
etanercept (Figure 3G). This indicated that the administra-
tion of etanercept enhanced the host control of influenza
virus replication. Interestingly, the mRNA level of TLR4,
the typical lipopolysaccharide (LPS) recognition receptor,
was dramatically increased in virus-infected mice, which
suggests that influenza virus infection resulting in compli-
cated cross-activations, including the activation of TLR4,
was also inhibited by etanercept (Figure 3B).
Figure 2 Etanercept reduced inflammatory cells infiltration and dampened the production of pro-inflammatory cytokines. On days 2
and 4 after infection, mice were euthanized, and the lungs were harvested to be homogenized individually and assayed for the following. (A)
Inflammatory cytokines (TNF-α, IFN-γ, IL-6) were analyzed with ELISA. (B through G) Major immune cells (macrophage/monocytes, neutrophils,
NK cells, B cells, CD4+ Th cells, and CD8+ Tc cells) were analyzed with flow cell cytometry. Four samples were picked up from mice per group each
time for assaying, and three replicated experiments were conducted. Data are presented as mean ± SD. #P≤ 0.05 compared with saline recipients.
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Figure 3 Etanercept inhibited the TLRs-NF-κB signaling pathway and enhanced host control of influenza replication. On days 2 and 4
after infection, mice were euthanized, and the lungs were harvested and assayed for the following: (A through C) Relative mRNA levels of TLR3,
TLR4, and TLR7. (D through F) The cascade genes (MyD88, TRIF, NF-κB, p65) in the NF-κB pathway. (G) Influenza M gene, indicating the replication
of influenza virus. (H through I) Immunohistochemical assay for phosphorylation of NF-κB p65 (dark yellow staining). The level of dark yellow
staining indicates the activation of the NF-κB signaling pathway. Data are presented as mean ± SD. #P ≤ 0.05 compared with saline recipients.
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the NF-κB signaling pathway, which was significantly
influenced by etanercept administration, as seen by the
downregulated mRNAs of MyD88, TRIF, and NF-κB p65
in etanercept-treated mice (Figure 3D-F). The immunohis-
tochemical results also clearly showed the phosphorylation
of the NF-κB p65 protein, indicating the activation of
the NF-κB signaling pathway in influenza virus-infected
mice. In contrast, etanercept significantly reduced the
phosphorylation of NF-κB p65 (Figure 3H through 3I).
These data strongly suggest that TNF-α may play an
important role in the burst of inflammatory cytokines,
recruitment of innate immune cells, and activation of
the NF-κB signaling pathway. Blocking TNF-α resulted
in improved survival and alleviated lung inflammation in
influenza-infected mice.
Discussion
TNF-α is traditionally considered a pro-inflammatory
cytokine [24,25]; however, recent emerging evidence also
identified an immune-regulatory role for it [26-28]. TNF-α
blockers, such as infliximab, adalimumab, certolizumab
pegol, golimumab, and etanercept, have been approved
for the treatment of rheumatoid arthritis and other
immune-mediated diseases. Thus, an interest exists in
investigating the use of inhibitors of TNF-α in the treat-
ment of infectious diseases [29,30].
In this study, we built up a simple and lethal influenza-
infection mice model to evaluate the effects of TNF in-
hibitors in influenza virus-induced severe viral pneumonia.
We administered etanercept to mice i.n. for a short period
(7 days). The results showed that local inhibition of TNF-
α could significantly reduce the high mortality in mice
induced by lethal influenza infection, which indicated
that TNF-α in lung tissue might play a pathologic role
in severe virus infection. Even intranasal administration
of etanercept (limited to the respiratory system) has been
proved to be effective for lethal influenza infection in this
research. Much remains to be investigated, such as patient
screening and possible second bacterial infections.
Many cytokines/chemokines are essential for the con-
trol of virus replication but also exacerbate morbidity
and tissue injury in mouse models [6]. IFN-γ activates
inflammatory cells and stimulates the expression of mul-
tiple cytokines and chemokines [31-33]. IL-6 expression
is directly linked to host morbidity [34,35], whereas
TNF-α secretion enhanced pulmonary injury. In this
study, a burst of IFN-γ, IL-6, and TNF-α was observed
in lethal influenza virus-infected mice, especially on
day 4 after infection. Blocking TNF-α obviously inhibited
the overproduction of these inflammatory cytokines,
which was consistent with the reduced lung injury and
low mortality in mice treated with etanercept. The
transcriptional and protein levels of other cytokinesand chemokines still must be determined to assess the
influence of etanercept.
Innate and adaptive immune cell infiltration contributes
to lung inflammation. Our study showed that blocking
TNF-α by using etanercept inhibited a large number of
infiltrated neutrophils and macrophage/monocytes in
influenza virus-infected mice. These results are similar
to the findings on the functional roles of macrophages/
neutrophils in virus replication and mortality [36]. Which
kind of cell in lung tissue is targeted mainly by etanercept
is under consideration in our future work. The influence
on other immune cells such as NK, B, CD4+, and CD8+
cells on days 2 and 4 after infection was not so clear in
mice treated with etanercept, and so more-detailed future
studies will be performed at day 7 (and later) after infection
to clarify this observation.
The NF-κB signaling pathway is a key factor controlling
inflammatory cytokine secretion and inflammatory cell
recruitment during virus infection. In this study, significant
activation of the NF-κB signaling pathway was observed
on days 2 or 4 after infection. This activation was inhibited
in mice treated with etanercept. TNF-α can trigger the
activation of the NF-κB signaling pathway via binding
to tumor necrosis factor receptor (TNFR) [37], and so
blocking TNF-α might inhibit the activation of NF-κB.
Toll-like receptors may activate the signaling cascade
in the NF-κB signaling pathway. The upregulation of TLR4,
which recognizes oxidized phospholipids generated by
reactive oxygen species (ROS) [38], was evidently inhibited
in etanercept-treated mice. This indicated that blocking
TNF-α might also alleviate influenza virus-induced
inflammatory injury. But whether the reduction of TLR4
is related to etanercept immunoadhesion is still unclear,
and it will be explored in our future work. The inhibited
virus-specific TLR3/7 correlated with reduced influenza
replication (M gene) in mice treated with etanercept,
which indicated that blocking TNF-α enhanced host
control of virus replication, but the elucidation of a pos-
sible mechanism requires more experimental investigation.
Conclusions
In summary, blocking TNF-α by using etanercept sup-
pressed the immunopathology and mortality in lethal
influenza-infected mice. These effects may be ascribed
to the inhibition of the cytokine bursts, reduced inflam-
matory cell infiltration, and downregulation of NF-κB
signaling pathways.
This is the first attempt at etanercept use in influenza
virus-induced viral pneumonia, and more details must be
clarified, such as the influences of IFN system, adaptive
immune responses, and different virus strains.
We envision that the use of etanercept (or other TNF
antagonists), in combination with antiviral strategies, may
be an effective tool against morbidity and mortality
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A virus.
Key messages
 TNF-α inhibitor etanercept significantly improved
survival and limited the lung inflammation in lethal
influenza-infected mice.
 Blocking TNF-α markedly inhibited the burst of
major inflammatory cytokines (for example, IL-6,
IFN-γ, and TNF-α) in the lung tissue of influenza-
infected mice.
 Blocking TNF-α reduced innate immune cell
infiltration (macrophage/monocytes and neutrophils)
in mouse lung tissue.
 Blocking TNF-α enhanced host control of influenza
virus replication.
 Blocking TNF-α downregulated the mRNA of
Toll-like receptors and inhibited the activation
of NF-κB signaling pathways.
Additional file
Additional file 1: Table S1. The primers for quantitative real time PCR.
These RT primers for M gene, TLR3, TLR-4, TLR-7, MyD88, TRIF, NF-κB, p65,
and GAPDH analysis. Using cDNAs as the template, quantitative real-time
PCR was carried out by using the SYBR Green PCR Master Mix (Applied
Biosystems) in a StepOne Plus Real-Time PCR Detection System (Applied
Biosystems), according to the manufacturer’s instructions. The mRNA
expression levels were normalized to the corresponding expression level
of the GAPDH housekeeping gene.
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